In recent years, China has undertaken massive healthcare reform, seen tremendous growth in its domestic pharmaceutical industry, and begun to play a larger role in global health and foreign aid efforts. These developments have made the Chinese healthcare industry and related sectors an important area of study and collaboration for U.S. policymakers, international businesses, and foreign aid recipients.
The CSIS Freeman Chair partners with the CSIS Global Health Policy Center to examine:
- China’s domestic healthcare reform
- Lessons from healthcare reforms in the U.S.
- Growth and innovation in China’s pharmaceutical industry
- China’s role in global health and foreign aid